^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IO-202

    i
    Company:
    Immune-Onc Therap
    Drug class:
    ILT-3 inhibitor
    Related drugs:
    Apply
    IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML (IO-202-CL-001) (NCT04372433)
    Phase 1
    Immune-Onc Therapeutics
    Completed
    Last update posted :
    02/14/2025
    Initiation :
    09/14/2020
    Primary completion :
    01/31/2025
    Completion :
    01/31/2025
    LILRB4
    |
    Venclexta (venetoclax) • azacitidine • IO-202
    Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors (NCT05309187)
    Phase 1
    Immune-Onc Therapeutics
    Completed
    Last update posted :
    06/04/2024
    Initiation :
    04/11/2022
    Primary completion :
    03/29/2024
    Completion :
    05/31/2024
    LILRB4
    |
    Keytruda (pembrolizumab) • IO-202